BIN2 inhibition suppress ovarian cancer progression meanwhile protect ovarian function through downregulating HDAC1 and RPS6 phosphorylation respectively.

Autor: Li, Cong‐Rong1,2,3,4 (AUTHOR), Xie, Shi‐Ya1,2,3,4 (AUTHOR), Zhang, Shu‐Ping1,2,3,4 (AUTHOR), Yang, Yan‐Jie1,2,3,4 (AUTHOR), Yang, Li‐Li5 (AUTHOR), Cao, Ying5 (AUTHOR), Wang, Li‐Li2 (AUTHOR), Zhu, Feng‐Yu2 (AUTHOR), Wang, Ruo‐Lei2 (AUTHOR), Yang, Zhi‐Xia1 (AUTHOR), Cui, Chen‐Chen6 (AUTHOR), Li, Yan‐Ru6 (AUTHOR), Xu, Jia‐Ning6 (AUTHOR), Yue, Feng6 (AUTHOR), Tian, Pei‐Zhe6 (AUTHOR), Wang, Qian6 (AUTHOR), Yao, Hong‐Jie7 (AUTHOR), Guan, Yi‐Chun8 (AUTHOR), Zhang, Shao‐Di6 (AUTHOR) zhangshd@126.com, Ying, Xiao‐Yan5 (AUTHOR) xiaoyanying_cool@163.com
Zdroj: Clinical & Translational Medicine. Oct2024, Vol. 14 Issue 10, p1-9. 9p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje